GSK PLC (LSE:GSK, NYSE:GSK)'s respiratory syncytial virus (RSV) vaccine, Arexvy, demonstrated robust long-term protection in a late-stage trial, targeting older adults, the pharma giant revealed on Wednesday.
The phase III study revealed the jab worked across two consecutive seasons, inclusive of participants with underlying medical conditions.
RSV, which generally induces symptoms similar to a cold, is a primary cause of pneumonia among toddlers and the elderly.
Arexvy, aiming to safeguard people aged 60 and above from the bug, received European regulators' approval earlier this month.
The drug has also secured the US Food and Drug Administration's (FDA) endorsement.
Market experts anticipate that the vaccine's sales could reach an annual peak of $2.5 billion.
However, evidence suggesting Arexvy's superior effectiveness compared to Pfizer's alternative could push the sales figure closer to $4 billion, paralleling the success of Shingrix, GSK's shingles vaccine.